Surfactis develops and commercialises nanocoatings that bring new properties on a broad variety of surfaces

Deputy C.E.O. of CYTOO S.A. and C.E.O. of CYTOO Inc.CYTOO is a biotechnology company focused on the development and commercialization of innovative and patented cell-based assays, based on first and best-in-class skin and muscle tissue models.CYTOO’s proprietary MyoScreen™ (skeletal muscle), FibroScreen™ (skin fibroblasts) and EpiScreen™ (skin epidermis) tissue models address different markets:• Muscle: pharmaceutical and biotechnology, animal health, and nutraceutical; • Skin: cosmetology and dermatology.MyoScreen™ has also served CYTOO to initiate its own drug discovery program using hypertrophy as a read out (possible therapeutic uses are sarcopenia, cachexia, musculo skeletal diseases including myopathies such as Duchenne Muscular Dystrophy and other rare genetic diseases).

A privately held, clinical-stage, biopharmaceutical corporation, Therabron is developing a new class of drugs from the secretoglobin family of proteins. Our lead product, recombinant human CC10 protein (rhCC10), is a potent anti-inflammatory agent for patients with respiratory diseases currently in Phase 2 in the US and Europe.

Recruited to prepare company IPO on Nasdaq and Paris market: putting in place all processes to be ready to behave as a publicly listed company, managing process with lawyers and banks, answering questions from SEC and other authorities. IPO was canceled just before roadshow. Focused on private investment and acquisition of companies, developed new business models for part of the business.